Form D · Biotechnology
Juno Therapeutics, Inc.
Seattle, WA · CIK 0001594864
Offering snapshot reported Oct 5, 2017 · SEC filing
- Reported sold
- $31.1M Offering amount: $31.1M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 26, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 5, 2017 | Initial | $31,091,407 | No comparison | 1 | SEC filing |
| Jun 29, 2017 | Amendment | $898,495,324 | $1,691,831vs Jul 6, 2016 | 2 | SEC filing |
| Jul 6, 2016 | Amendment | $896,803,493 | $46,999,997vs Jul 14, 2015 | 2 | SEC filing |
| Jul 14, 2015 | Initial | $849,803,496 | No comparison | 1 | SEC filing |
| Aug 14, 2014 | Initial | $85,499,985 | No comparison | 22 | SEC filing |
| May 8, 2014 | Initial | $28,423,971 | No comparison | 34 | SEC filing |
| Dec 26, 2013 | Initial | $6,667,672 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-296114
See the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 22, 2017.
Source: Form D, filed Oct 5, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sunil Agarwal | Executive |
| Robert Azelby | Executive |
| Hal Barron | Director |
| Hans Bishop | Director, Executive, Promoter |
| Bernard J. Cassidy | Executive |
| Larry Corey | Director |
| Thomas Daniel | Director |
| Anthony Evnin | Director |
| Jay Flatley | Director |
| Mark Frohlich | Executive, Promoter |
| Steven Harr | Executive |
| Richard Klausner | Director, Promoter |
| Rick Klausner | Director, Promoter |
| Hyam Levitsky | Executive |
| Robert Nelsen | Director, Promoter |
| Howard Pien | Director |
| Marc Tessier Lavigne | Director |
| Rupert Vessey | Director |
| Mary Agnes Wilderotter | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
400 Dexter Avenue North, Suite 1200
Seattle, WA, 98109
Seattle, WA, 98109